Histone deacetylases inhibitors in the treatment of retinal degenerative diseases: Overview and perspectives

Journal of Ophthalmology

Volumn 2015, Issue , 2015, Pages

  Zhang, Hua ^a   Dai, Xufeng ^a   Qi, Yan ^a   He, Ying ^a   Du, Wei ^b   Pang, Ji Jing ^a,b  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84934920037     PISSN: 2090004X     EISSN: 20900058     Source Type: Journal    
DOI: 10.1155/2015/250812     Document Type: Review

References (94)

1. C. Huang, E. A. Sloan, and C. F. Boerkoel, "Chromatin remodeling and human disease," Current Opinion in Genetics and Development, vol. 13, no. 3, pp. 246-252, 2003.
2. C. Simone and A. Peserico, "Physical and functional HAT/HDAC interplay regulates protein acetylation balance," Journal of Biomedicine and Biotechnology, vol. 2011, Article ID 371832, 10 pages, 2011.
3. G. Giannini, W. Cabri, C. Fattorusso, and M. Rodriquez, "Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives," Future Medicinal Chemistry, vol. 4, no. 11, pp. 1439-1460, 2012.
4. M.-J. Chuang, S.-T. Wu, S.-H. Tang et al., "The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation," PLoS ONE, vol. 8, no. 9, Article ID e73401, 2013.
5. W. Feng, B. Zhang, D. Cai, and X. Zou, "Terapeutic potential of histone deacetylase inhibitors in pancreatic cancer," Cancer Letters, vol. 347, no. 2, pp. 183-190, 2014.
6. D. Khabele, "The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer," Frontiers in Oncology, vol. 4, article 111, 2014.
7. M. A. Salvador, J. Wicinski, O. Cabaud et al., "The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression," Clinical Cancer Research, vol. 19, no. 23, pp. 6520-6531, 2013.
8. J. M. Mariadason, "HDACs and HDAC inhibitors in colon cancer," Epigenetics, vol. 3, no. 1, pp. 28-37, 2008.
9. D. Russo, C. Durante, S. Bulotta et al., "Targeting histone deacetylase in thyroid cancer," Expert Opinion on Terapeutic Targets, vol. 17, no. 2, pp. 179-193, 2013.
10. M. Ren, Y. Leng, M. Jeong, P. R. Leeds, and D.-M. Chuang, "Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction," Journal of Neuro-chemistry, vol. 89, no. 6, pp. 1358-1367, 2004.
11. J. K. Hyeon, M. Rowe, M. Ren, J. S. Hong, P. S. Chen, and D. M. Chuang, "Histone deacetylase inhibitors exhibit anti-infammatory and neuroprotective efects in a rat permanent ischemic model of stroke: multiple mechanisms of action," Journal of Pharmacology and Experimental Terapeutics, vol. 321, no. 3, pp. 892-901, 2007.
12. D.-M. Chuang, Y. Leng, Z. Marinova, H.-J. Kim, and C.-T. Chiu, "Multiple roles of HDAC inhibition in neurodegenerative conditions," Trends in Neurosciences, vol. 32, no. 11, pp. 591-601, 2009.
13. R. J. Ferrante, J. K. Kubilus, J. Lee et al., "Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice," The Journal of Neuroscience, vol. 23, no. 28, pp. 9418-9427, 2003.
14. Z. Zhang, X. Qin, N. Tong et al., "Valproic acid-mediated neuroprotection in retinal ischemia injury via histone deacety-lase inhibition and transcriptional activation," Experimental Eye Research, vol. 94, no. 1, pp. 98-108, 2012.
15. H. J. Kim, P. Leeds, and D.-M. Chuang, "The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain," Journal of Neurochemistry, vol. 110, no. 4, pp. 1226-1240, 2009.
16. S. Yasuda, M.-H. Liang, Z. Marinova, A. Yahyavi, and D.-M. Chuang, "The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons," Molecular Psychiatry, vol. 14, no. 1, pp. 51-59, 2009.
17. V. Marigo, "Programmed cell death in retinal degeneration: targeting apoptosis in photoreceptors as potential therapy for retinal degeneration," Cell Cycle, vol. 6, no. 6, pp. 652-655, 2007.
18. J. Sancho-Pelluz, B. Arango-Gonzalez, S. Kustermann et al., "Photoreceptor cell death mechanisms in inherited retinal degeneration," Molecular Neurobiology, vol. 38, no. 3, pp. 253-269, 2008.
19. M. M. LaVail, D. Yasumura, M. T. Matthes et al., "Protection of mouse photoreceptors by survival factors in retinal degenerations," Investigative Ophthalmology & Visual Science, vol. 39, no. 3, pp. 592-602, 1998.
20. M. Frasson, S. Picaud, T. Léveillard et al., "Glial cell line-derived neurotrophic factor induces histologic and functional protection of rod photoreceptors in the rd/rd mouse," Investigative Ophthalmology and Visual Science, vol. 40, no. 11, pp. 2724-2734, 1999.
21. M. Dokmanovic, C. Clarke, and P. A. Marks, "Histone deacety-lase inhibitors: overview and perspectives," Molecular Cancer Research, vol. 5, no. 10, pp. 981-989, 2007.
22. M. Yamaguchi, N. Tonou-Fujimori, A. Komori et al., "Histone deacetylase 1 regulates retinal neurogenesis in zebrafsh by suppressing Wnt ad Notch signaling pathways," Development, vol. 132, no. 13, pp. 3027-3043, 2005.
23. G. Lagger, D. O'Carroll, M. Rembold et al., "Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression," The EMBO Journal, vol. 21, no. 11, pp. 2672-2681, 2002.
24. D. Bandyopadhyay, J. L. Curry, Q. Lin et al., "Dynamic assembly of chromatin complexes during cellular senescence: Implications for the growth arrest of human melanocytic nevi," Aging Cell, vol. 6, no. 4, pp. 577-591, 2007.
25. R. Brunmeir, S. Lagger, and C. Seiser, "Histone deacetylase 1 and 2-controlled embryonic development and cell diferentiation," International Journal of Developmental Biology, vol. 53, no. 2-3, pp. 275-289, 2009.
26. C. L. Zhang, T. A. McKinsey, S. Chang, C. L. Antos, J. A. Hill, and E. N. Olson, "Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy," Cell, vol. 110, no. 4, pp. 479-488, 2002.
27. Y. Xiong, K. Zhao, J. Wu, Z. Xu, S. Jin, and Y. Q. Zhang, "HDAC6 mutations rescue human tau-induced microtubule defects in Drosophila," Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 12, pp. 4604-4609, 2013.
28. R. B. Vega, K. Matsuda, J. Oh et al., "Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis," Cell, vol. 119, no. 4, pp. 555-566, 2004.
29. I. Koutsounas, C. Giaginis, E. Patsouris, and S. Teocharis, "Current evidence for histone deacetylase inhibitors in pancreatic cancer," World Journal of Gastroenterology, vol. 19, no. 6, pp. 813-828, 2013.
30. M. Yoshida, M. Kijima, M. Akita, and T. Beppu, "Potent and specifc inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A," Journal of Biological Chemistry, vol. 265, no. 28, pp. 17174-17179, 1990.
31. M. Rahman, A. Kukita, T. Kukita, T. Shobuike, T. Nakamura, and O. Kohashi, "Two histone deacetylase inhibitors, tricho-statin A and sodium butyrate, suppress diferentiation into osteoclasts but not into macrophages," Blood, vol. 101, no. 9, pp. 3451-3459, 2003.
32. S. Belvedere, D. J. Witter, J. Yan, J. P. Secrist, V. Richon, and T. A. Miller, "Aminosuberoyl hydroxamic acids (ASHAs): a potent new class of HDAC inhibitors," Bioorganic and Medicinal Chemistry Letters, vol. 17, no. 14, pp. 3969-3971, 2007.
33. S. K. Ghosh, S. P. Perrine, R. M. Williams, and D. V. Faller, "Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents," Blood, vol. 119, no. 4, pp. 1008-1017, 2012.
34. W. K. Rasheed, R. W. Johnstone, and H. M. Prince, "Histone deacetylase inhibitors in cancer therapy," Expert Opinion on Investigational Drugs, vol. 16, no. 5, pp. 659-678, 2007.
35. H. M. Prince, M. J. Bishton, and S. J. Harrison, "Clinical studies of histone deacetylase inhibitors," Clinical Cancer Research, vol. 15, no. 12, pp. 3958-3969, 2009.
36. P. A. Marks, "The clinical development of histone deacetylase inhibitors as targeted anticancer drugs," Expert Opinion on Investigational Drugs, vol. 19, no. 9, pp. 1049-1066, 2010.
37. R. R. Rosato and S. Grant, "Histone deacetylase inhibitors in clinical development," Expert Opinion on Investigational Drugs, vol. 13, no. 1, pp. 21-38, 2004.
38. A. Kretsovali, C. Hadjimichael, and N. Charmpilas, "Histone deacetylase inhibitors in cell pluripotency, diferentiation, and reprogramming," Stem Cells International, vol. 2012, Article ID 184154, 10 pages, 2012.
39. J. Sancho-Pelluz, M. V. Alavi, A. Sahaboglu et al., "Excessive HDAC activation is critical for neurodegeneration in the rd1 mouse," Cell Death and Disease, vol. 1, no. 2, article e24, 2010.
40. B. Chen and C. L. Cepko, "Requirement of histone deacetylase activity for the expression of critical photoreceptor genes," BMC Developmental Biology, vol. 7, article 78, 2007.
41. D. M. Wallace, M. Donovan, and T. G. Cotter, "Histone deacetylase activity regulates Apaf-1 and caspase 3 expression in the developing mouse retina," Investigative Ophthalmology and Visual Science, vol. 47, no. 7, pp. 2765-2772, 2006.
42. F. Niu, X. Zhang, L. Chang et al., "Trichostatin A enhances OGD-astrocyte viability by inhibiting infammatory reaction mediated by NF-βB," Brain Research Bulletin, vol. 78, no. 6, pp. 342-346, 2009.
43. C. E. Crosson, S. K. Mani, S. Husain, O. Alsarraf, and D. R. Menick, "Inhibition of histone deacetylase protects the retina from ischemic injury," Investigative Ophthalmology and Visual Science, vol. 51, no. 7, pp. 3639-3645, 2010.
44. J. Fan, O. Alsarraf, M. Dahrouj et al., "Inhibition of HDAC2 protects the retina from ischemic injury," Investigative Ophthalmology and Visual Science, vol. 54, no. 6, pp. 4072-4080, 2013.
45. H.R. Pelzel, C.L. Schlamp, M. Waclawski, M.K. Shaw, andR.W. Nickells, "Silencing of Fem1cR3 gene expression in the DBA/2J mouse precedes retinal ganglion cell death and is associated with histone deacetylase activity," Investigative Ophthalmolog y and Visual Science, vol. 53, no. 3, pp. 1428-1435, 2012.
46. Y. Koriyama, K. Sugitani, K. Ogai, and S. Kato, "Neuritogenic activity of trichostatin a in adult rat retinal ganglion cells through acetylation of histone H3 lysine 9 and RARβ induction," Journal of Pharmacological Sciences, vol. 124, no. 1, pp. 112-116, 2014.
47. Y. Koriyama, Y. Takagi, K. Chiba et al., "Requirement of retinoic acid receptor β for genipin derivative-induced optic nerve regeneration in adult rat retina," PLoS ONE, vol. 8, Article ID e71252, 2013.
48. F. Paquet-Durand, J. Silva, T. Talukdar et al., "Excessive activation of poly(ADP-ribose) polymerase contributes to inherited photoreceptor degeneration in the retinal degeneration 1 mouse," Journal of Neuroscience, vol. 27, no. 38, pp. 10311-10319, 2007.
49. J. Sancho-Pelluz and F. Paquet-Durand, "HDAC inhibition prevents Rd1 mouse photoreceptor degeneration," Advances in Experimental Medicine and Biology, vol. 723, pp. 107-113, 2012.
50. W. Xiao, X. Chen, X. Liu, L. Luo, S. Ye, and Y. Liu, "Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and epithelial-mesenchymal transition in retinal pigment epithelium cells," Journal of Cellular and Molecular Medicine, vol. 18, no. 4, pp. 646-655, 2014.
51. D.-I. Sinn, S.-J. Kim, K. Chu et al., "Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacety-lase inhibition and transcriptional activation," Neurobiology of Disease, vol. 26, no. 2, pp. 464-472, 2007.
52. Y. Li, Z. Yuan, B. Liu et al., "Prevention of hypoxia-induced neuronal apoptosis through histone deacetylase inhibition," Journal of Trauma-Injury, Infection and Critical Care, vol. 64, no. 4, pp. 863-870, 2008.
53. Z. Zhang, N. Tong, Y. Gong et al., "Valproate protects the retina from endoplasmic reticulum stress-induced apoptosis afer ischemia-reperfusion injury," Neuroscience Letters, vol. 504, no. 2, pp. 88-92, 2011.
54. M. Shimazawa, Y. Inokuchi, Y. Ito et al., "Involvement of ER stress in retinal cell death," Molecular Vision, vol. 13, pp. 578-587, 2007.
55. E. Vecino, M. Hernández, and M. García, "Cell death in the developing vertebrate retina," International Journal of Developmental Biology, vol. 48, no. 8-9, pp. 965-974, 2004.
56. J. Biermann, P. Grieshaber, U. Goebel et al., "Valproic acid-mediated neuroprotection and regeneration in injured retinal ganglion cells," Investigative Ophthalmology & Visual Science, vol. 51, no. 1, pp. 526-534, 2010.
57. J. Biermann, J. Boyle, A. Pielen, and W. A. Lagrèze, "Histone deacetylase inhibitors sodium butyrate and valproic acid delay spontaneous cell death in purifed rat retinal ganglion cells," Molecular Vision, vol. 17, pp. 395-403, 2011.
58. Z. Z. Zhang, Y. Y. Gong, Y. H. Shi, W. Zhang, X. H. Qin, and X. W. Wu, "Valproate promotes survival of retinal ganglion cells in a rat model of optic nerve crush," Neuroscience, vol. 224, pp. 282-293, 2012.
59. Y. Koriyama, K. Sugitani, K. Ogai et al., "Heat shock protein 70 induction by valproic acid delays photoreceptor cell death by N-methyl-N-nitrosourea in mice," Journal of Neurochemistry, vol. 130, no. 5, pp. 707-719, 2014.
60. C. M. Clemson, R. Tzekov, M. Krebs, J. M. Checchi, C. Bigelow, and S. Kaushal, "Terapeutic potential of valproic acid for retinitis pigmentosa," British Journal of Ophthalmology, vol. 95, no. 1, pp. 89-93, 2011.
61. J. S. Chen, D. V. Faller, and R. A. Spanjaard, "Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics?" Current Cancer Drug Targets, vol. 3, no. 3, pp. 219-236, 2003.
62. R. Kuefer, M. D. Hofer, V. Altug et al., "Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer," British Journal of Cancer, vol. 90, no. 2, pp. 535-541, 2004.
63. H. Kamitani, S. Taniura, K. Watanabe, M. Sakamoto, T. Watan-abe, and T. Eling, "Histone acetylation may suppress human glioma cell proliferation when p21WAF/Cip1 and gelsolin are induced," Neuro-Oncology, vol. 4, no. 2, pp. 95-101, 2002.
64. X. X. Cao, I. Mohuiddin, F. Ece, D. J. McConkey, and W. R. Smythe, "Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothe-lioma," American Journal of Respiratory Cell and Molecular Biology, vol. 25, no. 5, pp. 562-568, 2001.
65. R. Claus, D. Günthner, and H. Letzguss, "Efects of feeding fat-coated butyrate on mucosal morphology and function in the small intestine of the pig," Journal of Animal Physiology and Animal Nutrition, vol. 91, no. 7-8, pp. 312-318, 2007.
66. J. Huuskonen, T. Suuronen, T. Nuutinen, S. Kyrylenko, and A. Salminen, "Regulation of microglial infammatory response by sodium butyrate and short-chain fatty acids," British Journal of Pharmacology, vol. 141, no. 5, pp. 874-880, 2004.
67. Q. Zhou, C.L. Dalgard, C. Wynder, andM.L. Doughty, "Histone deacetylase inhibitors SAHA and sodium butyrate block G1-to-S cell cycle progression in neurosphere formation by adult subventricular cells," BMC Neuroscience, vol. 12, article 50, 2011.
68. Y. Karasawa and S. Okisaka, "Inhibition of histone deacetylation by butyrate induces morphological changes in Y79 retinoblas-toma cells," Japanese Journal of Ophthalmology, vol. 48, no. 6, pp. 542-551, 2004.
69. G. Faraco, T. Pancani, L. Formentini et al., "Pharmacological inhibition of histone deacetylases by suberoylanilide hydrox-amic acid specifcally alters gene expression and reduces ischemic injury in the mouse brain," Molecular Pharmacology, vol. 70, no. 6, pp. 1876-1884, 2006.
70. S. H. Chen, H. M. Wu, B. Ossola et al., "Suberoylanilide hydrox-amic acid, a histone deacetylase inhibitor, protects dopaminer-gic neurons from neurotoxin-induced damage," British Journal of Pharmacology, vol. 165, no. 2, pp. 494-505, 2012.
71. J. P. Dompierre, J. D. Godin, B. C. Charrin et al., "Histone deacetylase 6 inhibition compensates for the transport defcit in Huntington's disease by increasing tubulin acetylation," Journal of Neuroscience, vol. 27, no. 13, pp. 3571-3583, 2007.
72. N. Agrawal, J. Pallos, N. Slepko et al., "Identifcation of combinatorial drug regimens for treatment of Huntington's disease using Drosophila," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 10, pp. 3777-3781, 2005.
73. A. Tandon, J. C. K. Tovey, M. R. Waggoner et al., "Vorinostat: a potent agent to prevent and treat laser-induced corneal haze," Journal of Refractive Surgery, vol. 28, no. 4, pp. 285-290, 2012.
74. X. Li, Q. Zhou, J. Hanus et al., "Inhibition of multiple pathogenic pathways by histone deacetylase inhibitor SAHA in a corneal alkali-burn injury model," Molecular Pharmaceutics, vol. 10, no. 1, pp. 307-318, 2013.
75. V. Poulaki, C. S. Mitsiades, V. Kotoula et al., "Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: Clinical implications," Investigative Ophthalmology and Visual Science, vol. 50, no. 9, pp. 4072-4079, 2009.
76. C. L. Dalgard, K. R. van Quill, and J. M. O'Brien, "Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma," Clinical Cancer Research, vol. 14, no. 10, pp. 3113-3123, 2008.
77. P. Chindasub, J. D. Lindsey, K. Duong-Polk, C. K. Leung, and R. N. Weinreb, "Inhibition of histone deacetylases 1 and 3 protects injured retinal ganglion cells," Investigative Ophthalmology and Visual Science, vol. 54, no. 1, pp. 96-102, 2013.
78. M. A. Yenari, J. Liu, Z. Zheng, Z. S. Vexler, J. E. Lee, and R. G. Gifard, "Antiapoptotic and anti-infammatory mechanisms of heat-shock protein protection," Annals of the New York Academy of Sciences, vol. 1053, pp. 74-83, 2005.
79. T. Ichiyama, K. Okada, J. M. Lipton, T. Matsubara, T. Hayashi, and S. Furukawa, "Sodium valproate inhibits production of TNF-β and IL-6 and activation of NF-βB," Brain Research, vol. 857, no. 1-2, pp. 246-251, 2000.
80. M. Kirsch, S. Schulz-Key, A. Wiese, S. Fuhrmann, and H. D. Hofmann, "Ciliary neurotrophic factor blocks rod photorecep-tor diferentiation from postmitotic precursor cells in vitro," Cell and Tissue Research, vol. 291, no. 2, pp. 207-216, 1998.
81. X. Wu, P. S. Chen, S. Dallas et al., "Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons," The International Journal of Neuropsychopharmacology, vol. 11, no. 8, pp. 1123-1134, 2008.
82. S. Azadi, L.E. Johnson, F. Paquet-Durand et al., "CNTF+ BDNF treatment and neuroprotective pathways in the rd1 mouse retina," Brain Research, vol. 1129, no. 1, pp. 116-129, 2007.
83. A. V. Cideciyan, T. S. Aleman, S. L. Boye et al., "Human gene therapy for RPE65 isomerase defciency activates the retinoid cycle of vision but with slow rod kinetics," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 39, pp. 15112-15117, 2008.
84. S. G. Jacobson, A. V. Cideciyan, R. Ratnakaram et al., "Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efcacy in 15 children and adults followed up to 3 years," Archives of Ophthalmology, vol. 130, no. 1, pp. 9-24, 2012.
85. J. W. B. Bainbridge, A. J. Smith, S. S. Barker et al., "Efect of gene therapy on visual function in Leber's congenital amaurosis," The New England Journal of Medicine, vol. 358, no. 21, pp. 2231-2239, 2008.
86. X. Li, W. Li, X. Dai et al., "Gene therapy rescues cone structure and function in the 3-month-old rd12 mouse: a model for midcourse RPE65 leber congenital amaurosis," Investigative Ophthalmology and Visual Science, vol. 52, no. 1, pp. 7-15, 2011.
87. A. V. Cideciyan, S. G. Jacobson, W. A. Beltran et al., "Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement," Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 6, pp. E517-E525, 2013.
88. B. R. Schwechter, L. E. Millet, and L. A. Levin, "Histone deacetylase inhibition-mediated diferentiation of RGC-5 cells and interaction with survival," Investigative Ophthalmology and Visual Science, vol. 48, no. 6, pp. 2845-2857, 2007.
89. X. Song, J. Wang, T. Zheng et al., "LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/stat3/akt pathway," Molecular Cancer, vol. 12, no. 1, article 114, 2013.
90. J. Savickiene, G. Treigyte, V. Borutinskaite, R. Navakauskiene, and K.-E. Magnusson, "The histone deacetylase inhibitor FK228 distinctly sensitizes the human leukemia cells to retinoic acid-induced diferentiation," Annals of the New York Academy of Sciences, vol. 1091, pp. 368-384, 2006.
91. E.-S. K. Assem, K. H. Peh, B. Y. C. Wan, B. J. Middleton, J. Dines, and C. M. Marson, "Efects of a selection of histone deacetylase inhibitors on mast cell activation and airway and colonic smooth muscle contraction," International Immunopharmacol-ogy, vol. 8, no. 13-14, pp. 1793-1801, 2008.
92. P. Kumar, S. Tripathi, and K. N. Pandey, "Histone deacetylase inhibitors modulate the transcriptional regulation of guanylyl cyclase/natriuretic peptide receptor-a gene: interactive roles of modifed histones, histone acetyltransferase, p300, and Sp1," Journal of Biological Chemistry, vol. 289, no. 10, pp. 6991-7002, 2014.
93. I. Svechnikova, P. M. Almqvist, and T. J. Ekström, "HDAC inhibitors efectively induce cell type-specifc diferentiation in human glioblastoma cell lines of diferent origin," International Journal of Oncology, vol. 32, no. 4, pp. 821-827, 2008.
94. Z. Khan, M. Akhtar, and T. J. Ekström, "HDAC inhibitor 4-phenylbutyrate preserves immature phenotype of human embryonic midbrain stem cells: implications for the involvement of DNA methyltransferase," International Journal of Molecular Medicine, vol. 28, no. 6, pp. 977-983, 2011.